Transgender persons face unique burdens of dermatologic conditions related to cutaneous effects of gender-affirming hormone therapy and procedures. Skin diseases in transgender patients often underdiagnosed and underrecognized despite potential for significant impairments quality of life and mental health from skin diseases. We discuss basic pathophysiology, diagnosis and treatment of common skin diseases in the transgender populations. For transmasculine patients, common conditions include acne vulgaris and male pattern hair loss. For transfeminine patients, common conditions include hirsutism, pseudofolliculitis barbae, and melasma. Post-procedural keloids and other cutaneous complications are discussed. Unique aspects of skin health in transgender persons should be considered in the context of multidisciplinary gender-affirming care.
We present histologic features of a locally advanced cutaneous squamous cell carcinoma (cSCC) treated with the programmed cell death protein-1 (PD-1) antagonist, pembrolizumab, with a partial response. This contributes to a growing body of literature supporting the efficacy of pembrolizumab in treatment of surgically unresectable cSCC. We also provide a detailed description of the histologic features, particularly keratin granulomata with adjacent lymphocytic aggregates and fibrosis, observed in cSCC under treatment with a PD-1 antagonist.histology, immunomodulation, squamous cell carcinoma, tumor-infiltrating lymphocytes 1 | INTRODUCTION Cutaneous squamous cell carcinoma (cSCC) is a common cancer that is effectively treated with surgical excision in most cases. A small percentage of cSCC are too locally extensive for surgery or radiation therapy to achieve complete remission and/or avoid significant cosmetic or functional impairment. Pembrolizumab is a programmed cell death protein 1 (PD-1) antagonist approved by the Food and Drug Administration for advanced or unresectable melanoma, non-small-cell lung cancer, and head and neck squamous cell carcinoma, among others. Prior case reports detail the effective use of off-label pembrolizumab to treat unresectable cSCC. 1-5 A phase II trial is currently evaluating the efficacy of pembrolizumab in adults with recurrent or metastatic cSCC. 6 In this case report, we present a patient with locally advanced cSCC of the left upper lip and columella treated with pembrolizumab, highlighting both its use in the treatment of an advanced cSCC and the unique histologic findings of multiple keratin granulomata with adjacent lymphocytic aggregates and fibrosis.
| CASE REPORTA 65-year-old white woman presented with a 5-year history of multiply recurrent left upper lip cSCC (Figure 1). She had been treated previously with (in chronological order) electrodesiccation and curettage, excision with repair, and Mohs micrographic surgery. Biopsy from the upper cutaneous lip at the time of presentation confirmed invasive welldifferentiated squamous cell carcinoma without definitive perineural invasion. The lesion measured 3.3 × 2.8 × 1.9 cm on computerized tomography (CT), extending from the left upper lip to the columella, abutting the maxilla without osseous erosion (Figure 2). The lesion was deemed unresectable due to the high risk of cosmetic and functional impairment. The patient then began a clinical trial of intravenous pembrolizumab at a flat dose of 200 mg every 3 weeks. The infusions were well tolerated without adverse reaction. After 6 months, the lesion showed remarkable clinical improvement and tumor depth on CT had decreased from 1.9 to 0.7 cm along with decreased enhancement and nodularity. Scouting skin biopsies were performed at 4 months to assess histologic response to immunotherapy. A scouting biopsy from the left upper cutaneous lip showed numerous keratin granulomata diffusely within the dermis with associated fibrosis and mixed inflammation, including aggregates of l...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.